This controlled release mechanism is particularly advantageous for administering thrombolytic agents such as tissue plasminogen activator (tPA) or urokinase, which can dissolve the blood clots that obstruct the blood flow in the brain during an ischemic stroke [140]. The gene discussed is PLAT; the disease is ischemic stroke.